NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives $34.50 Consensus Target Price from Analysts

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $34.50.

A number of equities research analysts have recently commented on the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a report on Tuesday, May 5th. Wall Street Zen lowered NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. BTIG Research restated a “buy” rating and issued a $10.00 price target on shares of NRx Pharmaceuticals in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a research note on Monday, August 10th. Finally, Ascendiant Capital Markets upped their price objective on NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a research note on Monday, April 27th.

NRx Pharmaceuticals Price Performance

Shares of NRx Pharmaceuticals stock opened at $3.56 on Friday. The firm’s fifty day simple moving average is $3.75 and its 200-day simple moving average is $3.00. NRx Pharmaceuticals has a 12 month low of $1.62 and a 12 month high of $5.05. The stock has a market capitalization of $154.15 million, a price-to-earnings ratio of -6.47 and a beta of 2.18.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Monday, August 17th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.33). The company had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $1.33 million. Analysts anticipate that NRx Pharmaceuticals will post -0.3 earnings per share for the current year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several large investors have recently modified their holdings of NRXP. Ethos Financial Group LLC lifted its holdings in shares of NRx Pharmaceuticals by 33.6% during the first quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after purchasing an additional 4,000 shares during the period. Global Retirement Partners LLC acquired a new position in NRx Pharmaceuticals in the 4th quarter valued at $107,000. Two Sigma Investments LP raised its position in NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after buying an additional 20,880 shares during the last quarter. State Street Corp raised its position in NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after buying an additional 10,700 shares during the last quarter. Finally, Bleakley Financial Group LLC acquired a new stake in shares of NRx Pharmaceuticals in the 4th quarter worth $318,000. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.